Ozempic Linked to Vision Loss and Cardiovascular Benefits Amid Safety Concerns

Recent studies highlight both the benefits and risks associated with semaglutide, marketed as Ozempic, a GLP-1 receptor agonist used for diabetes and weight management. Research from the National and Kapodistrian University of Athens suggests semaglutide may protect skin and eye cells, potentially lowering the risk of diabetic retinopathy, a condition that can cause blindness. University College London studies reveal that semaglutide reduces major adverse cardiovascular events, like heart attacks and strokes, by 20%, with benefits extending beyond weight loss. However, concerns have emerged about serious side effects, including a significantly increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition causing sudden vision loss, as reported by the American Academy of Ophthalmology and supported by data from over 100,000 patients. Additionally, dentists report a rise in "Ozempic teeth," linked to dry mouth and reduced saliva production caused by the drug, which can lead to dental erosion and gum disease. These findings underscore the need for careful patient monitoring and further research to balance the drug's therapeutic advantages and potential adverse effects.